Similarly, our observation that dynamic changes in D2R expression in tumour-associated endothelial cells depend on tumour responsiveness to chemotherapy and the activation status of D2R signalling may lead to a clinically useful biomarker. The gene discussed is DRD2; the disease is neoplasm.